Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 63(23): 14502-14521, 2020 12 10.
Artículo en Inglés | MEDLINE | ID: mdl-33054196

RESUMEN

We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be inactivated in blood as well as by the liver (dual-soft) while being stable in human skin. Compound 40 was selected as a clinical candidate as it was potent and rapidly degraded by blood and liver to inactive metabolites and because in preclinical studies it showed high exposure at the target organ: the skin. Preclinical and clinical data are presented confirming the value of the dual-soft concept in reducing systemic exposure.


Asunto(s)
Dermatitis Atópica/tratamiento farmacológico , Inhibidores de Fosfodiesterasa 4/farmacología , Animales , Descubrimiento de Drogas , Humanos , Inhibidores de Fosfodiesterasa 4/uso terapéutico
2.
J Med Chem ; 48(17): 5412-4, 2005 Aug 25.
Artículo en Inglés | MEDLINE | ID: mdl-16107139

RESUMEN

The known KDR inhibitor SU5416 and several analogues of the indolin-2-one family were surprisingly found to be highly efficacious in the EAE model, an established model for multiple sclerosis. The high in vivo effect could be correlated to in vitro inhibition of the pro-inflammatory cytokine IL-2. Activity following po administration was obtained with several analogues and via the use of prodrugs.


Asunto(s)
Encefalomielitis Autoinmune Experimental/metabolismo , Indoles/síntesis química , Esclerosis Múltiple/metabolismo , Animales , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Técnicas In Vitro , Indoles/química , Indoles/farmacología , Interleucina-2/antagonistas & inhibidores , Interleucina-2/biosíntesis , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/metabolismo , Ratones , Esclerosis Múltiple/tratamiento farmacológico , Relación Estructura-Actividad , Receptor 2 de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores
3.
J Med Chem ; 48(7): 2667-77, 2005 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-15801857

RESUMEN

This paper describes how the introduction of "cationic" aliphatic amino groups in the chalcone scaffold results in potent antibacterial compounds. It is shown that the most favorable position for the aliphatic amino group is the 2-position of the B-ring, in particular in combination with a lipophilic substituent in the 5-position of the B-ring. We demonstrate that the compounds act by unselective disruption of cell membranes. Introduction of an additional aliphatic amino group in the A-ring results in compounds that are selective for bacterial membranes combined with a high antibacterial activity against both Gram-positive and -negative pathogens. The most potent compound in this study (78) has an MIC value of 2 muM against methicillin resistant Staphylococus aureus.


Asunto(s)
Antibacterianos/síntesis química , Chalconas/síntesis química , Compuestos de Amonio Cuaternario/síntesis química , Antibacterianos/química , Antibacterianos/farmacología , Cationes , Chalconas/química , Chalconas/farmacología , Recuento de Colonia Microbiana , Diseño de Fármacos , Hemólisis/efectos de los fármacos , Humanos , Técnicas In Vitro , Cinética , Resistencia a la Meticilina , Pruebas de Sensibilidad Microbiana , Compuestos de Amonio Cuaternario/química , Compuestos de Amonio Cuaternario/farmacología , Staphylococcus aureus/efectos de los fármacos , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA